Bausch & Lomb
One Bausch & Lomb Place
245 articles with Bausch & Lomb
Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel
Bausch + Lomb announced the introduction of Soothe® Xtra Protection (XP) Preservative Free lubricant eye drops
Bausch + Lomb announced the introduction of Ocuvite® Blue Light eye vitamins
Valeant Pharmaceuticals will change its name to Bausch Health Companies Inc. in July of this year. The company will rebrand itself with the highly recognizable name of its subsidiary eye-care company Bausch + Lomb.
Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has approved the Bausch + Lomb ULTRA® family of contact lenses for extended wear of up to six nights and seven days of continuous wear.
Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting
Bausch + Lomb announced that nearly a dozen scientific posters will highlight the results of studies featuring several of the company's current product offerings and pipeline programs in its Consumer Health Care, Pharmaceuticals and Surgical businesses during the Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu from April 29 - May 3, 2018.
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program
Bausch + Lomb announced today that its ONE by ONE Recycling Program, the first contact lens recycling program of its kind, has recycled nearly 2.5 million used contact lenses, blister packs and top foils since the program launched in November 2016.
Bausch + Lomb Receives CE Mark From The European Commission for the Stellaris Elite Vision Enhancement System, Including The Vitesse Vitrectomy System
The Stellaris Elite platform is now available throughout greater Europe, including the 28 countries of the European Union, Iceland, Liechtenstein, Norway and Switzerland.
Lumify is the only over-the-counter eye drop with low-dose brimonidine for the treatment of eye redness.
Bausch + Lomb Begins Distribution of VYZULTA (Latanoprostene Bunod Ophthalmic Solution), 0.024% to U.S. Wholesalers
Valeant today announced that it has begun distributing VYZULTA.
Bausch & Lomb Helps to Recycle More Than One Million Units of Contact Lens Materials Within First Year of Launching the ONE by ONE Recycling Program
Valeant wholly owned subsidiary, Bausch & Lomb, today announced that its unique ONE by ONE Recycling Program has recycled a combined total of more than one million used contact lenses, blister packs and top foils in less than one year since its launch.
Bausch & Lomb and Nicox Announce FDA Approval of VYZULTA (latanoprostene Bunod Ophthalmic Solution), 0.024%
Valeant wholly owned subsidiary, Bausch & Lomb a leading global eye health company, and NicOx SA today announced that the FDA has approved the NDA for VYZULTA.
Bausch & Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025%